Dr Shawna Green Kuhn, DO | |
633d Medical Group, 77 Nealy Avenue, Joint Base Langley-eustis, VA 23665 | |
(757) 225-7630 | |
Not Available |
Full Name | Dr Shawna Green Kuhn |
---|---|
Gender | Female |
Speciality | |
Experience | Years |
Location | 633d Medical Group, Joint Base Langley-eustis, Virginia |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1831135623 | NPI | - | NPPES |
3929566 | Medicaid | TN |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | 02004861A (Indiana) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Shawna Green Kuhn, DO 633d Medical Group, 77 Nealy Avenue, Joint Base Langley-eustis, VA 23665 Ph: (757) 225-7630 | Dr Shawna Green Kuhn, DO 633d Medical Group, 77 Nealy Avenue, Joint Base Langley-eustis, VA 23665 Ph: (757) 225-7630 |
News Archive
Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development of products that prevent and remove microbial biofilms is pleased to announce that the Company has entered into a Cooperative Research and Development Agreement for Material Transfer (CRADA-MT) with the Walter Reed Army Institute of Research (WRAIR) in Silver Springs, Maryland.
New research just out in the journal Science Translational Medicine opens the door for the development of treatments capable of stopping Alzheimer's disease (AD) before its first symptoms, that is to say before any crucial damage occurs. In fact, if AD is a devastating disorder it is also an extremely slow one; it takes more than 10 years for the first symptoms to appear making this preclinical period (pre-symptoms) the ideal time to intervene.
A large-scale, multicenter study has shown that emergency body cooling does not improve survival rates or reduce brain injury in infants and children with out-of-hospital cardiac arrest more than normal temperature control.
Cell Therapeutics, Inc., a company focused on translating science into novel cancer therapies, today announced the initiation of the commercial launch of Pixuvri in the European Union with entry into Sweden, Denmark and Finland in September, to be followed by Austria and Norway in early October 2012 and Germany, United Kingdom and the Netherlands in November 2012.
The European Demographic Datasheet 2016, produced by demographers at the International Institute for Applied Systems Analysis and the Vienna Institute of Demography, provides a comprehensive look at key demographic indicators and main population trends for all European countries, including population projections for 2050.
› Verified 9 days ago